HighTower Advisors
PACB icon

HighTower Advisors’s Pacific Biosciences PACB Stock Holding History

HighTower Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed -$1K – 3460
2022
Q1 		$1K Buy
+10
New +$115 ﹤0.01% 3371

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HighTower Advisors's PACB Position: Q1 2026 in Review

HighTower Advisors increased its Pacific Biosciences (PACB) stake by 12% in Q1 2026, buying an estimated $2.12K and bringing the position to 11,287 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3772.

HighTower Advisors first reported a position in PACB in Q1 2017 and has held it in 24 quarters since. The position peaked at $3.09M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • HighTower Advisors held 11,287 shares of Pacific Biosciences worth $14.9K as of Q1 2026.
  • HighTower Advisors bought 1,184 Pacific Biosciences shares in Q1 2026, an estimated $2.12K.
  • Pacific Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3772 holding.
  • HighTower Advisors first reported a position in Pacific Biosciences in Q1 2017 and has held it in 24 quarters since.
  • HighTower Advisors's Pacific Biosciences position peaked at $3.09M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.